

Anthony E Lang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11819126/publications.pdf>

Version: 2024-02-01

542
papers

76,057
citations

767

119
h-index

642

256
g-index

573
all docs

573
docs citations

573
times ranked

42686
citing authors

#	ARTICLE	IF	CITATIONS
1	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders, 2008, 23, 2129-2170.	3.9	4,796
2	MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2015, 30, 1591-1601.	3.9	4,389
3	Parkinson's disease. Lancet, The, 2015, 386, 896-912.	13.7	4,079
4	Parkinson disease. Nature Reviews Disease Primers, 2017, 3, 17013.	30.5	3,048
5	Parkinson's Disease. New England Journal of Medicine, 1998, 339, 1044-1053.	27.0	1,876
6	Phenomenology and classification of dystonia: A consensus update. Movement Disorders, 2013, 28, 863-873.	3.9	1,754
7	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. New England Journal of Medicine, 2000, 342, 1484-1491.	27.0	1,467
8	Criteria for the diagnosis of corticobasal degeneration. Neurology, 2013, 80, 496-503.	1.1	1,445
9	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
10	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurology, The, 2008, 7, 583-590.	10.2	1,340
11	Impulse Control Disorders in Parkinson Disease. Archives of Neurology, 2010, 67, 589-95.	4.5	1,244
12	Parkinson's Disease. New England Journal of Medicine, 1998, 339, 1130-1143.	27.0	1,147
13	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders, 2007, 22, 41-47.	3.9	1,097
14	Pharmacological Treatment of Parkinson Disease. JAMA - Journal of the American Medical Association, 2014, 311, 1670.	7.4	1,097
15	MDS research criteria for prodromal Parkinson's disease. Movement Disorders, 2015, 30, 1600-1611.	3.9	1,033
16	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology, 2006, 59, 459-466.	5.3	890
17	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology, 2003, 54, 93-101.	5.3	820
18	Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes. Movement Disorders, 2006, 21, S290-S304.	3.9	811

#	ARTICLE	IF	CITATIONS
19	Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain, 2002, 125, 1196-1209.	7.6	645
20	Beta Oscillatory Activity in the Subthalamic Nucleus and Its Relation to Dopaminergic Response in Parkinson's Disease. Journal of Neurophysiology, 2006, 96, 3248-3256.	1.8	520
21	Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease. JAMA - Journal of the American Medical Association, 2002, 287, 455.	7.4	509
22	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Annals of Neurology, 2003, 54, S15-S19.	5.3	496
23	Technology in Parkinson's disease: Challenges and opportunities. Movement Disorders, 2016, 31, 1272-1282.	3.9	464
24	A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain, 2008, 131, 2720-2728.	7.6	460
25	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. JAMA Neurology, 2018, 75, 1132.	9.0	455
26	Posteroventral Medial Pallidotomy in Advanced Parkinson's Disease. New England Journal of Medicine, 1997, 337, 1036-1043.	27.0	453
27	Ten-Year Outcome of Subthalamic Stimulation in Parkinson Disease. Archives of Neurology, 2011, 68, 1550.	4.5	397
28	Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Movement Disorders, 2010, 25, 578-586.	3.9	382
29	Globus pallidus internus pallidotomy for generalized dystonia. Movement Disorders, 1997, 12, 865-870.	3.9	379
30	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Movement Disorders, 2014, 29, 454-462.	3.9	379
31	Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology, 2006, 66, 845-851.	1.1	371
32	Impulse control disorders in parkinson disease: A multicenter case-control study. Annals of Neurology, 2011, 69, 986-996.	5.3	361
33	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study. Annals of Neurology, 2010, 68, 18-27.	5.3	330
34	Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease. Archives of Neurology, 2009, 66, 1460.	4.5	326
35	Factors Associated With Dopaminergic Drug-Related Pathological Gambling in Parkinson Disease. Archives of Neurology, 2007, 64, 212.	4.5	322
36	Long-term Hardware-related Complications of Deep Brain Stimulation. Neurosurgery, 2002, 50, 1268-1276.	1.1	314

#	ARTICLE	IF	CITATIONS
37	Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. <i>Journal of Neurosurgery</i> , 2003, 99, 489-495.	1.6	306
38	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2009, 22, 430-436.	3.6	303
39	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology</i> , The, 2017, 16, 552-563.	10.2	303
40	Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. <i>Lancet Neurology</i> , The, 2004, 3, 309-316.	10.2	302
41	Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 716.	4.5	295
42	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. <i>Lancet Neurology</i> , The, 2007, 6, 652-662.	10.2	290
43	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , 2006, 129, 1059-1069.	7.6	286
44	Mutations in GNAL cause primary torsion dystonia. <i>Nature Genetics</i> , 2013, 45, 88-92.	21.4	281
45	Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , 2016, 12, 65-66.	10.1	279
46	Primary Dystonia Is More Responsive than Secondary Dystonia to Pallidal Interventions: Outcome after Pallidotomy or Pallidal Deep Brain Stimulation. <i>Neurosurgery</i> , 2004, 54, 613-621.	1.1	278
47	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , 2018, 33, 660-677.	3.9	275
48	Clinical Correlations With Lewy Body Pathology in <i>LRRK2</i> -Related Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 100.	9.0	272
49	Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. <i>Journal of Neurosurgery</i> , 2002, 97, 1152-1166.	1.6	267
50	A comparison of the mini mental state exam to the montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 297-299.	3.9	266
51	Long-Term Follow-up of Unilateral Pallidotomy in Advanced Parkinson's Disease. <i>New England Journal of Medicine</i> , 2000, 342, 1708-1714.	27.0	263
52	Deep brain stimulation: Preoperative issues. <i>Movement Disorders</i> , 2006, 21, S171-S196.	3.9	260
53	Short and long latency afferent inhibition in Parkinson's disease. <i>Brain</i> , 2003, 126, 1883-1894.	7.6	258
54	Neuropsychological Outcome of GPi Pallidotomy and GPi or STN Deep Brain Stimulation in Parkinson's Disease. <i>Brain and Cognition</i> , 2000, 42, 324-347.	1.8	255

#	ARTICLE	IF	CITATIONS
55	Î±-Synuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013, 73, 155-169.	5.3	255
56	Caffeine for treatment of Parkinson disease. <i>Neurology</i> , 2012, 79, 651-658.	1.1	252
57	Pallidal neuronal activity: Implications for models of dystonia. <i>Annals of Neurology</i> , 2003, 53, 480-488.	5.3	246
58	Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. <i>Movement Disorders</i> , 2006, 21, 1941-1946.	3.9	245
59	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology</i> , The, 2014, 13, 676-685.	10.2	245
60	Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists. <i>Movement Disorders</i> , 2004, 19, 656-662.	3.9	240
61	Interface between tauopathies and synucleinopathies: A tale of two proteins. <i>Annals of Neurology</i> , 2006, 59, 449-458.	5.3	240
62	Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. <i>Nature Genetics</i> , 2015, 47, 579-581.	21.4	237
63	Apraxia in movement disorders. <i>Brain</i> , 2005, 128, 1480-1497.	7.6	228
64	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002, 50, 1268-1276.	1.1	227
65	Stimulation of the subthalamic nucleus and impulsivity: Release your horses. <i>Annals of Neurology</i> , 2009, 66, 817-824.	5.3	225
66	Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018, 84, 797-811.	5.3	225
67	Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2019, 380, 315-324.	27.0	225
68	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015, 78, 248-257.	5.3	224
69	Practical guidelines for managing adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , 2015, 17, 599-609.	2.4	222
70	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007, 22, 2409-2417.	3.9	221
71	Distribution, type, and origin of Parkin mutations: Review and case studies. <i>Movement Disorders</i> , 2004, 19, 1146-1157.	3.9	219
72	Hemiballism: revisiting a classic disorder. <i>Lancet Neurology</i> , The, 2003, 2, 661-668.	10.2	217

#	ARTICLE	IF	CITATIONS
73	Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. <i>Nature Medicine</i> , 1997, 3, 671-674.	30.7	216
74	Bilateral globus pallidus stimulation for Huntington's disease. <i>Annals of Neurology</i> , 2004, 56, 290-294.	5.3	207
75	The prion hypothesis in Parkinson's disease: Braak to the future. <i>Acta Neuropathologica Communications</i> , 2013, 1, 2.	5.2	205
76	Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. <i>Neurology</i> , 2003, 61, 1601-1604.	1.1	204
77	Levodopaâ€carbidopa intestinal gel in advanced Parkinson's disease: Final 12â€month, openâ€label results. <i>Movement Disorders</i> , 2015, 30, 500-509.	3.9	199
78	Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , 2006, 59, 825-834.	5.3	195
79	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019, 92, 329-337.	1.1	194
80	Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: A functional MRI case study. <i>Movement Disorders</i> , 2003, 18, 1508-1516.	3.9	191
81	Parkinsonian syndromes associated with hydrocephalus: Case reports, a review of the literature, and pathophysiological hypotheses. <i>Movement Disorders</i> , 1994, 9, 508-520.	3.9	188
82	Diseaseâ€modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1442-1450.	3.9	188
83	Chorein detection for the diagnosis of choreaâ€acanthocytosis. <i>Annals of Neurology</i> , 2004, 56, 299-302.	5.3	186
84	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. <i>Movement Disorders</i> , 2002, 17, 303-312.	3.9	183
85	Predicting Motor Decline and Disability in Parkinson Disease. <i>Archives of Neurology</i> , 2002, 59, 1724.	4.5	179
86	Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. <i>Neurology</i> , 2013, 80, 1698-1701.	1.1	178
87	Teaching tape for the motor section of the toronto western spasmodic torticollis scale. <i>Movement Disorders</i> , 1997, 12, 570-575.	3.9	177
88	Imaging biomarkers in Parkinsonâ€™s disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , 2017, 6, 8.	8.0	177
89	Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated With Older (Ergot) vs Newer (Nonergot) Dopamine Agonists. <i>Archives of Neurology</i> , 2004, 61, 97.	4.5	174
90	Overview of the Extranigral Aspects of Parkinson Disease. <i>Archives of Neurology</i> , 2009, 66, 167-72.	4.5	172

#	ARTICLE	IF	CITATIONS
91	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders, 2018, 33, 1601-1608.	3.9	171
92	Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms. Brain, 2001, 124, 2105-2118.	7.6	168
93	Multiple system atrophyâ€“parkinsonism with slow progression and prolonged survival: A diagnostic catch. Movement Disorders, 2012, 27, 1186-1190.	3.9	164
94	Crossroads in GDNF therapy for Parkinson's disease. Movement Disorders, 2006, 21, 136-141.	3.9	163
95	The Fragile X Premutation Presenting as Essential Tremor. Archives of Neurology, 2003, 60, 117.	4.5	162
96	Analysis of the PINK1 Gene in a Large Cohort of Cases With Parkinson Disease. Archives of Neurology, 2004, 61, 1898-904.	4.5	162
97	Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. Brain, 1999, 122, 405-416.	7.6	153
98	Deep brain stimulation for Parkinson's disease: Patient selection and evaluation. Movement Disorders, 2002, 17, S94-S101.	3.9	150
99	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology, 2014, 82, 1791-1797.	1.1	147
100	Development of dyskinesias in a 5â€“year trial of ropinirole and L-dopa. Movement Disorders, 2006, 21, 1844-1850.	3.9	145
101	Biomarkerâ€“driven phenotyping in Parkinson's disease: A translational missing link in diseaseâ€“modifying clinical trials. Movement Disorders, 2017, 32, 319-324.	3.9	145
102	Gutâ€“brain axis and the spread of Î±â€“synuclein pathology: Vagal highway or dead end?. Movement Disorders, 2019, 34, 307-316.	3.9	144
103	Precision medicine for disease modification in Parkinson disease. Nature Reviews Neurology, 2017, 13, 119-126.	10.1	141
104	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. Neuropsychopharmacology, 2009, 34, 2758-2766.	5.4	140
105	Premotor Parkinson's disease: Concepts and definitions. Movement Disorders, 2012, 27, 608-616.	3.9	140
106	Uncovering the role of the insula in non-motor symptoms of Parkinsonâ€™s disease. Brain, 2014, 137, 2143-2154.	7.6	140
107	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Movement Disorders, 2009, 24, 1366-1374.	3.9	138
108	Psychogenic Dystonia: a Review of 18 Cases. Canadian Journal of Neurological Sciences, 1995, 22, 136-143.	0.5	137

#	ARTICLE	IF	CITATIONS
109	Progressive ataxia and palatal tremor (PAPT): Clinical and MRI assessment with review of palatal tremors. <i>Brain</i> , 2004, 127, 1252-1268.	7.6	134
110	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , 2017, 82, 503-513.	5.3	133
111	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010, 68, 963-968.	5.3	132
112	Association Between Early-Onset Parkinson Disease and 22q11.2 Deletion Syndrome. <i>JAMA Neurology</i> , 2013, 70, 1359.	9.0	132
113	Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. <i>Neurogenetics</i> , 2013, 14, 11-22.	1.4	131
114	Prediction of cognition in Parkinson's disease with a clinical genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology</i> , The, 2017, 16, 620-629.	10.2	131
115	The nonmotor symptoms of Parkinson's disease—An overview. <i>Movement Disorders</i> , 2010, 25, S123-30.	3.9	130
116	Colonic mucosal α -synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , 2015, 84, 609-616.	1.1	130
117	Neuronal Firing Rates and Patterns in the Globus Pallidus Internus of Patients With Cervical Dystonia Differ From Those With Parkinson's Disease. <i>Journal of Neurophysiology</i> , 2007, 98, 720-729.	1.8	129
118	A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials. <i>Movement Disorders</i> , 2011, 26, 775-783.	3.9	128
119	Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the <i>TUBB4</i> gene. <i>Annals of Neurology</i> , 2013, 73, 537-545.	5.3	128
120	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , The, 2013, 12, 514-524.	10.2	126
121	Gait abnormalities in psychogenic movement disorders. <i>Movement Disorders</i> , 2007, 22, 395-399.	3.9	125
122	Punding prevalence in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1179-1181.	3.9	125
123	The Nature and Time Course of Cortical Activation Following Subthalamic Stimulation in Parkinson's Disease. <i>Cerebral Cortex</i> , 2010, 20, 1926-1936.	2.9	125
124	From psychogenic movement disorder to functional movement disorder: It's time to change the name. <i>Movement Disorders</i> , 2014, 29, 849-852.	3.9	125
125	Antidepressant Treatment Outcomes of Psychogenic Movement Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1529-1534.	2.2	125
126	Extrastratial dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: A [11C] FLB-457 and PET study. <i>Neurobiology of Disease</i> , 2012, 48, 519-525.	4.4	123

#	ARTICLE	IF	CITATIONS
127	Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease With Modafinil. <i>Clinical Neuropharmacology</i> , 2002, 25, 111-114.	0.7	122
128	Predictors of deterioration in health-related quality of life in Parkinson's disease: Results from the DATATOP trial. <i>Movement Disorders</i> , 2008, 23, 653-659.	3.9	122
129	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013, 28, 1838-1846.	3.9	122
130	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	3.9	121
131	Î±-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , 2016, 39, 750-762.	8.6	120
132	Pathogenesis-Targeted, Disease-Modifying Therapies in Parkinson Disease. <i>Neurotherapeutics</i> , 2014, 11, 6-23.	4.4	119
133	Involvement of the cerebellothalamocortical pathway in Parkinson disease. <i>Annals of Neurology</i> , 2010, 68, 816-824.	5.3	117
134	Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. <i>Brain</i> , 2014, 137, 565-575.	7.6	116
135	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology</i> , The, 2019, 18, 865-879.	10.2	116
136	Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 1392-1397.	3.9	115
137	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	3.9	114
138	Placebo effect of medication cost in Parkinson disease. <i>Neurology</i> , 2015, 84, 794-802.	1.1	112
139	Involvement of human thalamus in the preparation of self-paced movement. <i>Brain</i> , 2004, 127, 2717-2731.	7.6	111
140	The progression of Parkinson disease. <i>Neurology</i> , 2007, 68, 948-952.	1.1	109
141	Phenotype-Specific Diagnosis of Functional (Psychogenic) Movement Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 32.	4.2	108
142	Analysis of the glucocerebrosidase gene in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 367-370.	3.9	107
143	<i>Helicobacter pylori</i> infection is associated with worse severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 221-225.	2.2	107
144	Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 990-997.	3.9	106

#	ARTICLE	IF	CITATIONS
145	Non-dopaminergic treatments in development for Parkinson's disease. <i>Lancet Neurology</i> , The, 2008, 7, 927-938.	10.2	106
146	Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. <i>Annals of Neurology</i> , 2009, 66, 110-114.	5.3	106
147	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 1077-1081.	3.9	106
148	The treatment of dystonic tremor: a systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 759-769.	1.9	105
149	The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 251-257.	1.7	104
150	Impairments of speed and amplitude of movement in Parkinson's disease: A pilot study. <i>Movement Disorders</i> , 2009, 24, 1001-1008.	3.9	104
151	Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. <i>Lancet Neurology</i> , The, 2020, 19, 452-461.	10.2	104
152	Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: Support for the existence of cognitive circuits in the human pallidum. <i>Brain</i> , 2000, 123, 746-758.	7.6	103
153	Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 130-135.	1.9	103
154	Disease modification and biomarker development in Parkinson disease. <i>Neurology</i> , 2020, 94, 481-494.	1.1	103
155	Caffeine as symptomatic treatment for Parkinson disease (Caf-CPD). <i>Neurology</i> , 2017, 89, 1795-1803.	1.1	102
156	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309942.	1.9	100
157	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology</i> , The, 2016, 15, 954-966.	10.2	100
158	Probiotics for Constipation in Parkinson Disease. <i>Neurology</i> , 2021, 96, e772-e782.	1.1	100
159	Historical and Clinical Features of Psychogenic Tremor: a Review of 70 Cases. <i>Canadian Journal of Neurological Sciences</i> , 1999, 26, 190-195.	0.5	99
160	Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure. <i>Movement Disorders</i> , 2006, 21, 1578-1594.	3.9	99
161	Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: A [¹⁵ O] H ₂ O PET study. <i>Human Brain Mapping</i> , 2009, 30, 3901-3909.	3.6	99
162	Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-omics. <i>Annals of Neurology</i> , 2021, 89, 546-559.	5.3	99

#	ARTICLE	IF	CITATIONS
163	Psychogenic Movement Disorders. Canadian Journal of Neurological Sciences, 2003, 30, S94-S100.	0.5	97
164	The cerebellothalamocortical pathway in essential tremor. Neurology, 2003, 60, 1985-1987.	1.1	97
165	Interhemispheric and ipsilateral connections in Parkinson's disease: Relation to mirror movements. Movement Disorders, 2007, 22, 813-821.	3.9	97
166	Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Annals of Neurology, 2004, 55, 761-765.	5.3	95
167	Manganese-Induced Parkinsonism Associated With Methcathinone (Ephedrone) Abuse. Archives of Neurology, 2007, 64, 886.	4.5	95
168	Characterization of REM-Sleep Associated Ponto-Geniculo-Occipital Waves in the Human Pons. Sleep, 2007, 30, 823-827.	1.1	95
169	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. PLoS ONE, 2015, 10, e0138721.	2.5	95
170	Parietal Pick's disease mimicking cortical-basal ganglionic degeneration. Neurology, 1994, 44, 1436-1436.	1.1	95
171	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. Journal of Medical Genetics, 2012, 49, 721-726.	3.2	94
172	The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nature Reviews Neurology, 2022, 18, 476-495.	10.1	94
173	Levodopa-related motor complications-Phenomenology. Movement Disorders, 2008, 23, S509-S514.	3.9	93
174	Psychogenic facial movement disorders: Clinical features and associated conditions. Movement Disorders, 2012, 27, 1544-1551.	3.9	93
175	Stereotypies: A critical appraisal and suggestion of a clinically useful definition. Movement Disorders, 2012, 27, 179-185.	3.9	93
176	Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. Annals of Neurology, 2015, 77, 269-280.	5.3	93
177	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	3.9	93
178	Extrastriatal dopaminergic dysfunction in tourette syndrome. Annals of Neurology, 2010, 67, 170-181.	5.3	92
179	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. Movement Disorders, 2015, 30, 150-159.	3.9	92
180	The many faces of corticobasal degeneration. Parkinsonism and Related Disorders, 2007, 13, S336-S340.	2.2	91

#	ARTICLE	IF	CITATIONS
181	Integrated safety of levodopaâ€carbidoa intestinal gel from prospective clinical trials. Movement Disorders, 2016, 31, 538-546.	3.9	91
182	Benign hereditary chorea: Clinical, genetic, and pathological findings. Annals of Neurology, 2003, 54, 244-247.	5.3	90
183	Corticobasal Ganglionic Degeneration and Progressive Supranuclear Palsy Presenting with Cognitive Decline. Brain Pathology, 1998, 8, 355-365.	4.1	89
184	Investigation of C9orf72 in 4 Neurodegenerative Disorders. Archives of Neurology, 2012, 69, 1583.	4.5	89
185	Tics and functional tic-like movements. Neurology, 2019, 93, 750-758.	1.1	89
186	Impairment of motor cortex activation and deactivation in Parkinson's disease. Clinical Neurophysiology, 2001, 112, 600-607.	1.5	88
187	Vascular <scp>P</scp>arkinsonism: <scp>D</scp>econstructing a <scp>S</scp>yndrome. Movement Disorders, 2015, 30, 886-894.	3.9	88
188	Mutation analysis of <i>CHCHD10</i> in different neurodegenerative diseases. Brain, 2015, 138, e380-e380.	7.6	86
189	Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: A case report. Movement Disorders, 2004, 19, 969-972.	3.9	84
190	Chronic acquired hepatocerebral degeneration: Case reports and new insights. Movement Disorders, 1995, 10, 714-722.	3.9	83
191	Surgery for Parkinson Disease. Archives of Neurology, 2000, 57, 1118.	4.5	83
192	Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. Nature Medicine, 2010, 16, 1223-1226.	30.7	83
193	Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. Brain, 2011, 134, 2096-2105.	7.6	83
194	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. Neuropsychopharmacology, 2009, 34, 2758-66.	5.4	83
195	New developments in understanding the etiology of Parkinson's disease and in its treatment. Current Opinion in Neurobiology, 1998, 8, 783-790.	4.2	82
196	The new definition and diagnostic criteria of Parkinson's disease. Lancet Neurology, The, 2016, 15, 546-548.	10.2	82
197	Posttraumatic painful torticollis. Movement Disorders, 2003, 18, 1482-1491.	3.9	81
198	Dopaminergic transplantation for parkinson's disease: Current status and future prospects. Annals of Neurology, 2009, 66, 591-596.	5.3	80

#	ARTICLE	IF	CITATIONS
199	Movement Disorders on YouTube â€” Caveat Spectator. New England Journal of Medicine, 2011, 365, 1160-1161.	27.0	77
200	Outcome measurement in functional neurological disorder: a systematic review and recommendations. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 638-649.	1.9	77
201	Stimulation of the Subthalamic Nucleus in Parkinson's Disease Does Not Produce Striatal Dopamine Release. Neurosurgery, 2003, 53, 1095-1105.	1.1	76
202	Functional neurological disorders in Parkinson disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 566-571.	1.9	76
203	â€œUnder pressureâ€™: is there a link between orthostatic hypotension and cognitive impairment in Î±-synucleinopathies?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1311-1321.	1.9	75
204	Pallidal Stimulation in Parkinson's Disease Patients with a Prior Unilateral Pallidotomy. Canadian Journal of Neurological Sciences, 1998, 25, 300-305.	0.5	74
205	Alimentary, my dear Watson? The challenges of enteric Î±-synuclein as a Parkinson's disease biomarker. Movement Disorders, 2014, 29, 444-450.	3.9	74
206	Essential pitfalls in â€œessentialâ€™ tremor. Movement Disorders, 2017, 32, 325-331.	3.9	74
207	Peroxisomal D-bifunctional protein deficiency. Neurology, 2014, 82, 963-968.	1.1	73
208	Clinical and neural responses to cognitive behavioral therapy for functional tremor. Neurology, 2019, 93, e1787-e1798.	1.1	73
209	Firing rates of pallidal neurons are similar in Huntingtonâ€™s and Parkinsonâ€™s disease patients. Experimental Brain Research, 2005, 166, 230-236.	1.5	72
210	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). Canadian Journal of Neurological Sciences, 2017, 44, 196-202.	0.5	72
211	Criteria for deep-brain stimulation in Parkinsonâ€™s disease: review and analysis. Expert Review of Neurotherapeutics, 2006, 6, 1695-1705.	2.8	71
212	Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 56, 58-64.	2.2	71
213	Dystonia and Parkinson's disease: What is the relationship?. Neurobiology of Disease, 2019, 132, 104462.	4.4	71
214	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. Translational Neurodegeneration, 2019, 8, 28.	8.0	70
215	Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. Current Opinion in Neurology, 2018, 31, 484-490.	3.6	69
216	Subthalamic nucleusâ€™ deep brain stimulation for early motor complications in Parkinson's diseaseâ€™the EARLYSTIM trial: Early is not always better. Movement Disorders, 2014, 29, 1751-1756.	3.9	68

#	ARTICLE	IF	CITATIONS
217	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , 2016, 31, 290-298.	3.9	68
218	Timing of deep brain stimulation in Parkinson disease: A need for reappraisal?. <i>Annals of Neurology</i> , 2013, 73, 565-575.	5.3	67
219	Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , 2018, 17, 179-187.	2.7	67
220	Hemiballism in multiple sclerosis. <i>Movement Disorders</i> , 1988, 3, 88-94.	3.9	66
221	Involvement of the Basal Ganglia and Cerebellar Motor Pathways in the Preparation of Self-Initiated and Externally Triggered Movements in Humans. <i>Journal of Neuroscience</i> , 2007, 27, 6029-6036.	3.6	65
222	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020, 11, 572976.	2.4	65
223	Dopamineâ€agonists and impulsivity in Parkinson's disease: Impulsive choices vs. impulsive actions. <i>Human Brain Mapping</i> , 2014, 35, 2499-2506.	3.6	64
224	Cortical Plasticity Induction by Pairing Subthalamic Nucleus Deep-Brain Stimulation and Primary Motor Cortical Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2016, 36, 396-404.	3.6	64
225	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimerâ€™s Disease and Parkinsonâ€™s Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 120.	3.4	64
226	Alterations of striatal neurons in benign hereditary chorea. <i>Movement Disorders</i> , 2005, 20, 1353-1357.	3.9	63
227	Behavioral effects of levodopa. <i>Movement Disorders</i> , 2015, 30, 90-102.	3.9	63
228	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 102-106.	2.2	63
229	GDNF and Parkinsonâ€™s Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , 2020, 10, 875-891.	2.8	63
230	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021, 27, 1451-1457.	30.7	63
231	Deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, S168-S170.	3.9	62
232	Hereditary parkinsonism: Parkinson disease lookâ€alikesâ€”An algorithm for clinicians to â€œPARKâ€ genes and beyond. <i>Movement Disorders</i> , 2009, 24, 2042-2058.	3.9	62
233	ATP13A2 variants in earlyâ€onset Parkinson's disease patients and controls. <i>Movement Disorders</i> , 2009, 24, 2104-2111.	3.9	62
234	Striatonigral Degeneration: Iron Deposition in Putamen Correlates with the Slit-like Void Signal of Magnetic Resonance Imaging. <i>Canadian Journal of Neurological Sciences</i> , 1994, 21, 311-318.	0.5	61

#	ARTICLE	IF	CITATIONS
235	Response to clozapine in a clinically identifiable subtype of schizophrenia. <i>British Journal of Psychiatry</i> , 2015, 206, 484-491.	2.8	61
236	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinson's Disease</i> , 2016, 2, .	5.3	61
237	Common Myths in the Use of Levodopa in Parkinson Disease. <i>JAMA Neurology</i> , 2017, 74, 633.	9.0	60
238	Sustained relief of dystonia following cessation of deep brain stimulation. <i>Movement Disorders</i> , 2007, 22, 1958-1962.	3.9	59
239	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 86-95.	3.9	59
240	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY- α PD III). <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 360-368.	3.7	59
241	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary. <i>Neurology</i> , 2021, 97, 942-957.	1.1	58
242	Motor neuron disease-inclusion dementia presenting as cortical-basal ganglionic degeneration. <i>Movement Disorders</i> , 1999, 14, 674-680.	3.9	57
243	Nonsteroidal α -inflammatory Use and α -LRRK2 α Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020, 35, 1755-1764.	3.9	57
244	rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: A PET study. <i>Movement Disorders</i> , 2008, 23, 1051-1054.	3.9	56
245	Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. <i>Neurology</i> , 2014, 82, 2250-2251.	1.1	56
246	Global investigation and meta-analysis of the α -C9orf72 α (G α 4 α C α 2 α) α repeat in Parkinson disease. <i>Neurology</i> , 2014, 83, 1906-1913.	1.1	56
247	Single Pulse Stimulation of the Human Subthalamic Nucleus Facilitates the Motor Cortex at Short Intervals. <i>Journal of Neurophysiology</i> , 2004, 92, 1937-1943.	1.8	55
248	Characteristic head drops and axial extension in advanced chorea α -acanthocytosis. <i>Movement Disorders</i> , 2010, 25, 1487-1491.	3.9	54
249	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). <i>Journal of Alzheimer's Disease</i> , 2017, 59, 707-721.	2.6	54
250	Neuropsychological and behavioral changes and weight gain after medial pallidotomy. <i>Annals of Neurology</i> , 1997, 41, 834-835.	5.3	53
251	Letters to the Editor. <i>Movement Disorders</i> , 1998, 13, 851-854.	3.9	53
252	Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 259.	3.4	53

#	ARTICLE	IF	CITATIONS
253	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , 2016, 139, 2050-2062.	7.6	53
254	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 109-110.	2.2	53
255	When and how should treatment be started in Parkinson disease?. <i>Neurology</i> , 2009, 72, S39-43.	1.1	52
256	Deep Brain Stimulator Electrodes Used for Lesioning: Proof of Principle. <i>Neurosurgery</i> , 2001, 49, 363-369.	1.1	51
257	Caffeine consumption and risk of dyskinesia in <scp>CALM</scp>â€<scp>PD</scp>. <i>Movement Disorders</i> , 2013, 28, 380-383.	3.9	51
258	Pallidal deep brain stimulation modulates cortical excitability and plasticity. <i>Annals of Neurology</i> , 2018, 83, 352-362.	5.3	51
259	Anticholinergics in Adult-Onset Focal Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1982, 9, 313-319.	0.5	50
260	Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. <i>Journal of Neurosurgery</i> , 2005, 103, 246-251.	1.6	50
261	Benign hereditary chorea revisited: A journey to understanding. <i>Movement Disorders</i> , 2007, 22, 2297-2305.	3.9	50
262	Persistent Hemiballismus with Lesions Outside the Subthalamic Nucleus. <i>Canadian Journal of Neurological Sciences</i> , 1985, 12, 125-128.	0.5	49
263	Perioperative Problems in Parkinson's Disease and Their Management: Apomorphine with Rectal Domperidone. <i>Canadian Journal of Neurological Sciences</i> , 1996, 23, 198-203.	0.5	49
264	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2015, 167, 639-645.	1.2	49
265	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force â€“ An Update. <i>Movement Disorders</i> , 2022, 37, 905-935.	3.9	49
266	A longitudinal program for biomarker development in Parkinson's disease: A feasibility study. <i>Movement Disorders</i> , 2009, 24, 2081-2090.	3.9	48
267	Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. <i>Movement Disorders</i> , 2016, 31, 1243-1247.	3.9	48
268	Unusual tremor syndromes: know in order to recognise. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1191-1203.	1.9	48
269	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3150-3160.	4.3	48
270	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinson's Disease</i> , 2018, 8, S59-S64.	2.8	48

#	ARTICLE	IF	CITATIONS
271	Pallidotomy for Parkinson's Disease. Neurosurgery Clinics of North America, 1998, 9, 325-336.	1.7	47
272	Impact of Mild Cognitive Impairment on Health-Related Quality of Life in Parkinson's Disease. Dementia and Geriatric Cognitive Disorders, 2013, 36, 67-75.	1.5	47
273	Long-term double-blind unilateral pedunculopontine area stimulation in Parkinson's disease. Movement Disorders, 2016, 31, 1570-1574.	3.9	47
274	Subthalamic nucleus deep brain stimulation for parkinson's disease after successful pallidotomy: Clinical and electrophysiological observations. Movement Disorders, 2004, 19, 1209-1214.	3.9	46
275	Psychogenic movement disorders. Current Opinion in Neurology, 2005, 18, 399-404.	3.6	46
276	The spectrum of orolingual tremor—A proposed classification system. Movement Disorders, 2008, 23, 159-167.	3.9	46
277	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurology, The, 2012, 11, 643-650.	10.2	46
278	Associated movement disorders in orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 725-729.	1.9	46
279	Levodopa challenge test: indications, protocol, and guide. Journal of Neurology, 2021, 268, 3135-3143.	3.6	46
280	Acquired neurosyphilis presenting as movement disorders. Movement Disorders, 2012, 27, 690-695.	3.9	45
281	Another face of placebo: The lessebo effect in Parkinson disease. Neurology, 2014, 82, 1402-1409.	1.1	45
282	Altered gut microbiome and metabolome in patients with multiple system atrophy. Movement Disorders, 2018, 33, 174-176.	3.9	45
283	<sc><i>Helicobacter pylori</i></sc> Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. Movement Disorders, 2020, 35, 2250-2260.	3.9	45
284	Motor Cortical Stimulation for Parkinsonism in Multiple System Atrophy. Archives of Neurology, 2003, 60, 1554.	4.5	44
285	Caffeine in Parkinson's disease: A pilot open-label, dose-escalation study. Movement Disorders, 2011, 26, 2427-2431.	3.9	44
286	What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. Journal of Neuropsychiatry and Clinical Neurosciences, 2020, 32, 79-84.	1.8	44
287	Abolishing the 1-year rule: How much evidence will be enough?. Movement Disorders, 2016, 31, 1623-1627.	3.9	43
288	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. Movement Disorders, 2019, 34, 676-681.	3.9	43

#	ARTICLE	IF	CITATIONS
289	Electrophysiological features of myoclonusâ€dystonia. Movement Disorders, 2008, 23, 2055-2061.	3.9	42
290	Psychogenic movement disorders: Past developments, current status, and future directions. Movement Disorders, 2011, 26, 1175-1186.	3.9	42
291	Refinement of the DYT15 locus in myoclonus dystonia. Movement Disorders, 2007, 22, 888-892.	3.9	41
292	Imaging changes associated with cognitive abnormalities in Parkinsonâ€™s disease. Brain Structure and Function, 2015, 220, 2249-2261.	2.3	41
293	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinsonâ€™s disease. Brain, 2017, 140, 1371-1383.	7.6	41
294	Treatment of Parkinsonâ€™s disease with agents other than Levodopa and Dopamine Agonists: controversies and new approaches. Canadian Journal of Neurological Sciences, 1984, 11, 210-220.	0.5	40
295	Corticobasal degeneration: Selected developments. Movement Disorders, 2003, 18, 51-56.	3.9	40
296	The curious case of phenocopies in families with genetic Parkinson's disease. Movement Disorders, 2011, 26, 1793-1802.	3.9	40
297	Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 364-368.	1.9	40
298	<i>Movement</i> Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments. Movement Disorders, 2013, 28, 1980-1986.	3.9	39
299	Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease. Neurology, 2015, 85, 425-432.	1.1	39
300	Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. Journal of Neurosurgery, 1999, 90, 468-477.	1.6	38
301	Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double-blind trials. Movement Disorders, 2011, 26, 1464-1476.	3.9	38
302	Withdrawal akathisia: Case reports and a proposed classification of chronic akathisia. Movement Disorders, 2004, 9, 188-192.	3.9	37
303	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: Differential effects on bradykinesia. Movement Disorders, 2007, 22, 328-333.	3.9	37
304	What is â€œessentialâ€ about essential tremor? A diagnostic placeholder. Movement Disorders, 2018, 33, 58-61.	3.9	37
305	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	3.9	37
306	Gestes antagonistes in psychogenic dystonia. Movement Disorders, 2004, 19, 331-332.	3.9	36

#	ARTICLE	IF	CITATIONS
307	Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. <i>Neurogenetics</i> , 2005, 6, 151-158.	1.4	36
308	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. <i>Neurobiology of Aging</i> , 2015, 36, 545.e9-545.e14.	3.1	36
309	Contribution of insula in Parkinson's disease: A quantitative meta-analysis study. <i>Human Brain Mapping</i> , 2016, 37, 1375-1392.	3.6	36
310	[18F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , 2018, 223, 589-595.	2.3	36
311	High Dose Anticholinergic Therapy in Adult Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1986, 13, 42-46.	0.5	35
312	Deep Brain Stimulator Electrodes Used for Lesioning: Proof of Principle. <i>Neurosurgery</i> , 2001, 49, 363-369.	1.1	35
313	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology</i> , The, 2006, 5, 200-202.	10.2	35
314	Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. <i>Parkinsonism and Related Disorders</i> , 2016, 22, 80-86.	2.2	35
315	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , 2018, 90, e2059-e2067.	1.1	35
316	Subdural motor cortex stimulation in Parkinson's disease does not modify movement-related rCBF pattern. <i>Movement Disorders</i> , 2007, 22, 2113-2116.	3.9	33
317	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. <i>Parkinsonism and Related Disorders</i> , 2016, 28, 41-48.	2.2	33
318	Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies. <i>Neuroscience Letters</i> , 2018, 665, 18-21.	2.1	33
319	Natural History of Oppenheim's Dystonia (DYT1) in Israel. <i>Journal of Child Neurology</i> , 2003, 18, 325-330.	1.4	32
320	Double-blind study of pramipexole, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 738-746.	3.9	32
321	Movement disorders in patients with diabetes mellitus. <i>Journal of the Neurological Sciences</i> , 2012, 314, 5-11.	0.6	32
322	Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links SCN1A to early onset parkinsonian features. <i>Epilepsia</i> , 2017, 58, e44-e48.	5.1	32
323	Letters to the editor. <i>Movement Disorders</i> , 1995, 10, 527-529.	3.9	31
324	Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. <i>Neuroscience Letters</i> , 2004, 372, 226-229.	2.1	31

#	ARTICLE	IF	CITATIONS
325	Homozygous and heterozygous <i>PINK1</i> mutations: Considerations for diagnosis and care of Parkinson's disease patients. <i>Movement Disorders</i> , 2006, 21, 875-879.	3.9	31
326	Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. <i>Movement Disorders</i> , 2017, 32, 193-202.	3.9	31
327	ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 512-520.	1.5	31
328	Alphamethylparatyrosine and Tetrabenazine in Movement Disorders. <i>Clinical Neuropharmacology</i> , 1982, 5, 375-388.	0.7	30
329	Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: The spectrum of hemiparkinsonism-hemiatrophy syndrome. <i>Movement Disorders</i> , 1995, 10, 489-495.	3.9	30
330	The perioperative management of Parkinson's disease revisited. <i>Neurologic Clinics</i> , 2004, 22, 367-377.	1.8	30
331	Antidepressants in the Treatment of Psychosis With Comorbid Depression in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 90-92.	0.7	30
332	Development of a Non-Motor Fluctuation Assessment Instrument for Parkinson Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-13.	1.1	30
333	Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes. <i>Human Brain Mapping</i> , 2017, 38, 283-292.	3.6	30
334	Genomewide Association Studies of <i>LRRK2</i> Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021, 90, 76-88.	5.3	30
335	Neurodegenerative disease and the evolution of art: The effects of presumed corticobasal degeneration in a professional artist. <i>Movement Disorders</i> , 2003, 18, 294-302.	3.9	29
336	Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 893-903.	3.9	29
337	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer's Disease, Parkinson's Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , 2019, 13, 1259.	2.8	29
338	The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes. <i>Movement Disorders</i> , 2021, 36, 594-598.	3.9	28
339	Microelectrode Recordings Define the Ventral Posteromedial Pallidotomy Target. <i>Stereotactic and Functional Neurosurgery</i> , 1998, 71, 153-163.	1.5	27
340	Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. <i>Movement Disorders</i> , 2005, 20, 371-377.	3.9	27
341	The Value of GRE, ADC and Routine MRI in Distinguishing Parkinsonian Disorders. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, 389-402.	0.5	27
342	Integrated Therapy for Functional Movement Disorders: Time for a Change. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 169-174.	1.5	27

#	ARTICLE	IF	CITATIONS
343	'Don't delay, start today': delaying levodopa does not delay motor complications. <i>Brain</i> , 2014, 137, 2628-2630.	7.6	26
344	Repurposing drugs to treat L-DOPA-induced dyskinesia in Parkinson's disease. <i>Neuropharmacology</i> , 2019, 147, 11-27.	4.1	26
345	Neuronal intranuclear inclusion disease: Two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1274-1279.	3.9	25
346	Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 222-225.	2.2	25
347	Unfreezing of gait in patients with Parkinson's disease. <i>Lancet Neurology</i> , The, 2015, 14, 675-677.	10.2	25
348	Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease. <i>Movement Disorders</i> , 2018, 33, 1700-1711.	3.9	25
349	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2146-2159.	1.2	25
350	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018, 125, 1373-1379.	2.8	25
351	Clinical Findings in a Large Family With a Parkin Ex3 ⁴⁰ Mutation. <i>Archives of Neurology</i> , 2004, 61, 701.	4.5	24
352	Reduced Intracortical and Interhemispheric Inhibitions in Corticobasal Syndrome. <i>Journal of Clinical Neurophysiology</i> , 2008, 25, 304-312.	1.7	24
353	Dystonia in complex regional pain syndrome type I. <i>Annals of Neurology</i> , 2010, 67, 412-414.	5.3	24
354	Pedunculopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 613-616.	1.9	24
355	Alternating Hemiplegia of Childhood as a New Presentation of Adenylate Cyclase 5-Mutation-Associated Disease: A Report of Two Cases. <i>Journal of Pediatrics</i> , 2017, 181, 306-308.e1.	1.8	24
356	Corticobasal degeneration. <i>International Review of Neurobiology</i> , 2019, 149, 87-136.	2.0	24
357	Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 961-962.	1.9	24
358	Telemedicine in Movement Disorders: Leçons du COVID-19. <i>Movement Disorders</i> , 2020, 35, 1893-1896.	3.9	24
359	Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0153852.	2.5	24
360	Pallidotomy for Tremor. <i>Movement Disorders</i> , 1998, 13, 107-110.	3.9	23

#	ARTICLE	IF	CITATIONS
361	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopaâ€”carbidopa intestinal gel infusion. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 968-971.	2.2	23
362	The Interaction Between Neuroinflammation and Î²-Amyloid in Cognitive Decline in Parkinsonâ€™s Disease. <i>Molecular Neurobiology</i> , 2020, 57, 492-501.	4.0	23
363	Myoclonus in complex regional pain syndrome. <i>Movement Disorders</i> , 2009, 24, 314-316.	3.9	22
364	Longâ€”term effect of unilateral pallidotomy on levodopaâ€”induced dyskinesia. <i>Movement Disorders</i> , 2010, 25, 1496-1498.	3.9	22
365	Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 116-124.	1.5	22
366	Antidepressants and psychosis in Parkinson disease: a case series. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 601-604.	2.7	21
367	Diagnostic delay in Parkinson's disease caused by PRKN mutations. <i>Parkinsonism and Related Disorders</i> , 2019, 63, 217-220.	2.2	21
368	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 412-423.	1.9	21
369	Neuroprotection in Parkinson's disease: and now for something completely different?. <i>Lancet Neurology</i> , The, 2006, 5, 990-991.	10.2	20
370	The G2019S <i>LRRK2</i> mutation in Brazilian patients with Parkinson's disease: Phenotype in monozygotic twins. <i>Movement Disorders</i> , 2008, 23, 290-294.	3.9	20
371	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBSâ€”PD). <i>Movement Disorders</i> , 2010, 25, 1530-1537.	3.9	20
372	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2011, 26, 608-613.	3.9	20
373	Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. <i>Journal of Neurosurgery</i> , 2011, 114, 1428-1431.	1.6	20
374	Implications of nocturnal symptoms towards the early diagnosis of Parkinsonâ€™s disease. <i>Journal of Neural Transmission</i> , 2014, 121, 49-57.	2.8	19
375	Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy. <i>Movement Disorders</i> , 2017, 32, 1465-1473.	3.9	19
376	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018, 9, 1123.	2.4	19
377	Case 1, 1994: Rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. <i>Movement Disorders</i> , 1994, 9, 358-366.	3.9	18
378	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. <i>Movement Disorders</i> , 2011, 26, 1348-1352.	3.9	18

#	ARTICLE	IF	CITATIONS
379	Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 610-614.	3.9	18
380	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 503-510.	2.8	18
381	Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 105-118.	2.6	18
382	Parkinson's Disease, <i>NOTCH3</i> Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020, 35, 2090-2095.	3.9	18
383	Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. , 2017, 8, 261.		18
384	Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. <i>Movement Disorders</i> , 2003, 18, 942-948.	3.9	17
385	Orthostatic tremor in progressive supranuclear palsy. <i>Movement Disorders</i> , 2007, 22, 1192-1194.	3.9	17
386	Initiating dopaminergic treatment in Parkinson's disease. <i>Lancet</i> , The, 2014, 384, 1164-1166.	13.7	17
387	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 915-918.	2.2	17
388	Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [¹¹ C]-PHNO and [¹¹ C]raclopride positron emission tomography imaging study. <i>Human Brain Mapping</i> , 2015, 36, 2592-2601.	3.6	17
389	<p>Orthostatic hypotension and dementia incidence: links and implications</p>. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2181-2194.	2.2	17
390	Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?. <i>Movement Disorders</i> , 2021, 36, 1483-1484.	3.9	17
391	Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease. <i>PLoS ONE</i> , 2017, 12, e0173944.	2.5	17
392	Deep Bayesian networks for uncertainty estimation and adversarial resistance of white matter hyperintensity segmentation. <i>Human Brain Mapping</i> , 2022, 43, 2089-2108.	3.6	17
393	Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. <i>Movement Disorders</i> , 1996, 11, 448-449.	3.9	16
394	Diagnosing psychogenic movement disorders— which criteria should be used in clinical practice?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 134-135.	2.5	16
395	Clinical heterogeneity in Progressive Supranuclear Palsy: Challenges to diagnosis, pathogenesis and future therapies. <i>Movement Disorders</i> , 2014, 29, 1707-1709.	3.9	16
396	Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2016, 38, 217.e7-217.e8.	3.1	16

#	ARTICLE	IF	CITATIONS
397	Expanding the phenomenology of benign hereditary chorea: Evolution from chorea to myoclonus and dystonia. <i>Movement Disorders</i> , 2011, 26, 2296-2297.	3.9	15
398	Designing Clinical Trials for Dystonia. <i>Neurotherapeutics</i> , 2014, 11, 117-127.	4.4	15
399	Paroxysmal Asymmetric Dystonic Arm Posturing—A Less Recognized but Characteristic Manifestation of ATP1A3-related disease. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 312-315.	1.5	15
400	Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. <i>Parkinsonism and Related Disorders</i> , 2020, 74, 25-27.	2.2	15
401	A case of neurosyphilis presenting with myoclonus, cerebellar ataxia, and speech disturbance. <i>Movement Disorders</i> , 2012, 27, 794-794.	3.9	14
402	Clinicopathological review of pallidonigroluysian atrophy. <i>Movement Disorders</i> , 2013, 28, 274-281.	3.9	14
403	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 67-69.	1.5	14
404	Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway. <i>Neurobiology of Disease</i> , 2019, 124, 176-182.	4.4	14
405	The evidence for multidisciplinary care in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 539-549.	2.8	14
406	Improved Segmentation of the Intracranial and Ventricular Volumes in Populations with Cerebrovascular Lesions and Atrophy Using 3D CNNs. <i>Neuroinformatics</i> , 2021, 19, 597-618.	2.8	14
407	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021, 6, 80.	3.8	14
408	GDNF in Parkinson's disease: The perils of post-hoc power. <i>Journal of Neuroscience Methods</i> , 2007, 163, 193-196.	2.5	13
409	Functional/psychogenic movement disorders: Do we know what they are?. <i>Movement Disorders</i> , 2014, 29, 1696-1697.	3.9	13
410	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019, 31, 361-367.	1.8	13
411	Action Myoclonus and Seizure in Kufor-Rakeb Syndrome. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 195-199.	1.5	13
412	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018, 33, 960-965.	3.9	12
413	Sleep-related motor and behavioral disorders: Recent advances and new entities. <i>Movement Disorders</i> , 2018, 33, 1042-1055.	3.9	12
414	Rapidly progressive sporadic dentatorubral pallidoluysian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. <i>Movement Disorders</i> , 2006, 21, 2251-2254.	3.9	11

#	ARTICLE	IF	CITATIONS
415	Reversible dopamine agonist induced anterocollis in a multiple system atrophy patient. Movement Disorders, 2007, 22, 2292-2293.	3.9	11
416	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. Movement Disorders, 2009, 24, 2370-2378.	3.9	11
417	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 43, 151-156.	4.8	11
418	Dancing Dorsal Quadrilaterals. JAMA Neurology, 2019, 76, 351.	9.0	11
419	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism and Related Disorders, 2020, 79, 121-126.	2.2	11
420	Parkinson's Disease and COVID-19: Do We Need to Be More Patient?. Movement Disorders, 2021, 36, 277-277.	3.9	11
421	Small and Large Magnetic Resonance Imaging-Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. Movement Disorders, 2022, 37, 1304-1309.	3.9	11
422	Neuronal activity in the globus pallidus of multiple system atrophy patients. Movement Disorders, 2004, 19, 1485-1492.	3.9	10
423	Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. Journal of Human Genetics, 2011, 56, 671-675.	2.3	10
424	Voxel-Based Imaging of Translocator Protein 18Kda (TSPO) in High-Resolution PET. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 348-350.	4.3	10
425	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. Movement Disorders Clinical Practice, 2016, 3, 184-187.	1.5	10
426	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. Journal of Parkinson's Disease, 2018, 8, 131-139.	2.8	10
427	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease. Clinical Autonomic Research, 2019, 29, 603-614.	2.5	10
428	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. Parkinsonism and Related Disorders, 2020, 80, 127-132.	2.2	10
429	Diagnosing functional neurological disorder: seeing the whole picture. CNS Spectrums, 2021, 26, 593-600.	1.2	10
430	Sporadic case of dentatorubral pallidoluysian atrophy with no CAG repeat expansion and no intranuclear inclusions. Movement Disorders, 2004, 19, 580-583.	3.9	9
431	Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy. Experimental Brain Research, 2010, 206, 1-13.	1.5	9
432	The grasp reflex: A symptom in need of treatment. Movement Disorders, 2010, 25, 2479-2485.	3.9	9

#	ARTICLE	IF	CITATIONS
433	LRRK2 and Parkin mutations in a family with parkinsonism—Lack of genotype—phenotype correlation. <i>Neurobiology of Aging</i> , 2010, 31, 721-722.	3.1	9
434	Genome-wide variant by serum urate interaction in Parkinson's disease. <i>Annals of Neurology</i> , 2015, 78, 731-741.	5.3	9
435	DYT-TUBB4A (DYT4 Dystonia). <i>Neurology</i> , 2021, 96, e1887-e1897.	1.1	9
436	Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. <i>BMC Neurology</i> , 2021, 21, 459.	1.8	9
437	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. <i>Movement Disorders</i> , 2022, 37, 1265-1271.	3.9	9
438	Insights into brain function through the examination of art: the influence of neurodegenerative diseases. <i>NeuroReport</i> , 2004, 15, 933-937.	1.2	8
439	Successful treatment of functional palatal tremor: Insights into pathogenesis and management. <i>Movement Disorders</i> , 2015, 30, 875-876.	3.9	8
440	Paroxysmal Hemiballism/Hemichorea Resulting from Transient Ischemic Attacks. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 303-305.	1.5	8
441	Oculogyric crises in PLA2G6 associated neurodegeneration. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 111-112.	2.2	8
442	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 200-203.	2.2	8
443	The retina as a window to the basal ganglia: Systematic review of the potential link between retinopathy and hyperkinetic disorders in diabetes. <i>Parkinsonism and Related Disorders</i> , 2020, 80, 194-198.	2.2	8
444	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021, 105, 378.e1-378.e9.	3.1	8
445	Protracted course progressive supranuclear palsy. <i>European Journal of Neurology</i> , 2022, 29, 2220-2231.	3.3	8
446	Manipulating the dopaminergic system in Parkinson's disease. , 1987, 32, 51-76.		7
447	—Weight-holding tremor—: An unusual task-specific form of essential tremor?. <i>Movement Disorders</i> , 1995, 10, 228-229.	3.9	7
448	Letters to the editor. <i>Movement Disorders</i> , 1995, 10, 235-237.	3.9	7
449	FIXED DYSTONIA UNRESPONSIVE TO PALLIDAL STIMULATION IMPROVED BY MOTOR CORTEX STIMULATION. <i>Neurology</i> , 2007, 69, 1062-1063.	1.1	7
450	Early-onset tardive dyskinesia in a neuroleptic-naïve patient exposed to low-dose quetiapine. <i>Movement Disorders</i> , 2011, 26, 2297-2298.	3.9	7

#	ARTICLE	IF	CITATIONS
451	Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's Disease. Movement Disorders Clinical Practice, 2018, 5, 66-74.	1.5	7
452	The clinical significance of lower limb tremors. Parkinsonism and Related Disorders, 2019, 65, 165-171.	2.2	7
453	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. Frontiers in Neurology, 2020, 11, 574.	2.4	7
454	Primary brain calcification due to a homozygous MYORG mutation causing isolated paroxysmal kinesigenic dyskinesia. Brain, 2020, 143, e36-e36.	7.6	7
455	Movement Disorders Associated with Hypogonadism. Movement Disorders Clinical Practice, 2021, 8, 997-1011.	1.5	7
456	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. International Journal of Molecular Sciences, 2021, 22, 7292.	4.1	7
457	Myoclonus in parkinsonian disorders. Advances in Neurology, 2002, 89, 77-83.	0.8	7
458	Motor and non-motor fluctuations. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 84, 157-184.	1.8	6
459	Tremor in Spinocerebellar Ataxia Type 12. Movement Disorders Clinical Practice, 2014, 1, 76-78.	1.5	6
460	Dystonic Pseudo Foot Drop. Movement Disorders Clinical Practice, 2015, 2, 295-298.	1.5	6
461	Placebos in clinical trials: unravelling a complex phenomenon. Lancet Neurology, The, 2017, 16, 28-29.	10.2	6
462	Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. Cmaj, 2018, 190, E50-E52.	2.0	6
463	Successful pallidotomy for post-hyperglycemic hemichorea-ballism. Parkinsonism and Related Disorders, 2019, 61, 228-230.	2.2	6
464	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. Parkinsonism and Related Disorders, 2020, 71, 44-45.	2.2	6
465	Movement Disorders: Diagnosis and Assessment. , 2008, , 293-325.		6
466	Tremor-Dominant Pantothenate Kinase-associated Neurodegeneration. Movement Disorders Clinical Practice, 2017, 4, 772-774.	1.5	5
467	Tracking the course of prodromal Parkinson's disease. Brain, 2017, 140, 259-262.	7.6	5
468	A Distinct EEG Marker of Celiac Disease-Related Cortical Myoclonus. Movement Disorders, 2021, 36, 999-1005.	3.9	5

#	ARTICLE	IF	CITATIONS
469	Axial Impairment Following Deep Brain Stimulation in Parkinson's Disease: A Surgicogenomic Approach. <i>Journal of Parkinson's Disease</i> , 2022, 12, 117-128.	2.8	5
470	<scp>DYT4</scp> (<scp>DYT4</scp> Dystonia): Clinical Anthology of 11 Cases and Systematized Review. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 659-675.	1.5	5
471	Essential palatal tremor. <i>Movement Disorders</i> , 2001, 16, 1202-1203.	3.9	4
472	Rapidly progressive behavioral changes and parkinsonism in a 68-year-old man. <i>Movement Disorders</i> , 2004, 19, 534-543.	3.9	4
473	Progress in Clinical Neurosciences: A Forum on the Early Management of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2005, 32, 277-286.	0.5	4
474	Stem cell therapy for Parkinson's disease. <i>Annals of Neurology</i> , 2012, 71, 283-283.	5.3	4
475	Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. <i>Biomarkers in Medicine</i> , 2015, 9, 89-97.	1.4	4
476	Comment on "Is it Useful to Classify PSP and CBD as Different Disorders?". <i>Movement Disorders Clinical Practice</i> , 2018, 5, 564-565.	1.5	4
477	Isolated Abdominal Motor Seizures of Mesial Parietal Origin: Epileptic Belly Dancing?. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 396-399.	1.5	4
478	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1561-1569.	2.8	4
479	<scp>Age-Related</scp> Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , 2020, 35, 1239-1245.	3.9	4
480	Preferences for Communication About End-of-Life Care in Atypical Parkinsonism. <i>Movement Disorders</i> , 2021, 36, 2116-2125.	3.9	4
481	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 1964-1967.	3.9	4
482	Spinocerebellar Ataxia 40: Another Etiology Underlying Essential Tremor Syndrome. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 944-946.	1.5	4
483	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. <i>GeroScience</i> , 2022, 44, 1575-1598.	4.6	4
484	Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 252-252.	3.9	3
485	Hemiballism "Hemichorea". , 2013, , 151-161.		3
486	Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 447-448.	0.5	3

#	ARTICLE	IF	CITATIONS
487	Will New Genetic Techniques Like Exome Sequencing Obviate the Need for Clinical Expertise? No. Movement Disorders Clinical Practice, 2017, 4, 39-41.	1.5	3
488	Infantile-onset hand dystonia with intellectual disability. Neurology, 2018, 90, 333-335.	1.1	3
489	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. Movement Disorders, 2018, 33, 1195-1203.	3.9	3
490	Interhemispheric pathways in agenesis of the corpus callosum and Parkinson's disease. Brain Stimulation, 2020, 13, 360-362.	1.6	3
491	Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1047-1055.	2.8	3
492	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. Movement Disorders, 2021, 36, 171-177.	3.9	3
493	Bilingualism in Parkinson's disease: Relationship to cognition and quality of life. Journal of Clinical and Experimental Neuropsychology, 2021, 43, 199-212.	1.3	3
494	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. Frontiers in Psychiatry, 2022, 13, 816465.	2.6	3
495	Targeted copy number variant identification across the neurodegenerative disease spectrum. Molecular Genetics & Genomic Medicine, 0, , .	1.2	3
496	Structural and functional magnetic resonance imaging in neurodegenerative diseases. , 2005, , 253-289.		2
497	Multiple system atrophy. , 2005, , 623-662.		2
498	In pursuit of prodromal Parkinson's disease. Lancet Neurology, The, 2015, 14, 27-28.	10.2	2
499	Is there even such a thing as 'idiopathic normal pressure hydrocephalus'? Annals of Neurology, 2017, 82, 1032-1032.	5.3	2
500	Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration. Canadian Journal of Neurological Sciences, 2019, 46, 782-784.	0.5	2
501	Jumping to overcome freezing of gait while turning in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 64, 349-351.	2.2	2
502	Initiating pharmacotherapy in early Parkinson's disease. Lancet Neurology, The, 2020, 19, 643-644.	10.2	2
503	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. Parkinsonism and Related Disorders, 2020, 74, 80.	2.2	2
504	Is clinical assessment enough? Moving towards early differentiation of neurodegenerative parkinsonisms. Brain, 2021, 144, 1040-1042.	7.6	2

#	ARTICLE	IF	CITATIONS
505	Reply to: "The Logic and Pitfalls of Parkinson's as Brain-First Subtypes"; Movement Disorders, 2021, 36, 786-787.	3.9	2
506	Dream Enactment Behavior Disorder Associated with Pallido-Nigro-Luysian Degeneration and Tau Proteinopathy. Movement Disorders Clinical Practice, 2021, 8, 594-599.	1.5	2
507	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. Clinical Autonomic Research, 2021, 31, 729-736.	2.5	2
508	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 1: Genetic Disorders. Movement Disorders Clinical Practice, 2022, 9, 297-310.	1.5	2
509	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders. Movement Disorders Clinical Practice, 2022, 9, 311-325.	1.5	2
510	Case of a Man with Hemichorea and Behavioral Changes: "A Red Herring". Movement Disorders Clinical Practice, 2022, 9, 501-507.	1.5	2
511	69-Year-old man with gait disturbance and parkinsonism. Movement Disorders, 2001, 16, 548-561.	3.9	1
512	Selected genetically engineered models relevant to human neurodegenerative disease. , 2005, , 176-195.		1
513	Therapy of the Motor Features of Parkinson's Disease. Blue Books of Neurology, 2010, 34, 252-272.	0.1	1
514	Crossing the borders between neurology and psychiatry in functional neurological disorders. Movement Disorders, 2011, 26, 1373-1374.	3.9	1
515	Commentary. Movement Disorders, 2013, 28, 1806-1807.	3.9	1
516	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. Movement Disorders Clinical Practice, 2016, 3, 53-58.	1.5	1
517	Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders. Clinical Neurophysiology Practice, 2021, 6, 103-108.	1.4	1
518	Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. Canadian Journal of Neurological Sciences, 2021, , 1-5.	0.5	1
519	Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease. Movement Disorders, 2021, 36, 1125-1125.	3.9	1
520	Teaching Video Neurolmage: "Weighing in on an Unusual Tremor. Neurology, 2021, 97, e970-e971.	1.1	1
521	Irreversible extreme freezing of gait after dopamine agonist withdrawal. Clinical Case Reports (discontinued), 2021, 9, e04712.	0.5	1
522	The Discovery of α -Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. Movement Disorders Clinical Practice, 2021, 8, 1189-1193.	1.5	1

#	ARTICLE	IF	CITATIONS
523	Oculogyric Crisis Phenotype of Levodopa-Induced Ocular Dyskinesia. Movement Disorders Clinical Practice, 0, , .	1.5	1
524	Pallidal neuronal activity in multiple system atrophy type P and Parkinson's disease. Parkinsonism and Related Disorders, 2022, 101, 15-17.	2.2	1
525	Corticobasal degeneration. , 2005, , 682-696.		0
526	Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus. , 2005, , 227-250.		0
527	Approach to the patient presenting with parkinsonism. , 2005, , 551-560.		0
528	Current and potential treatments of Parkinson's disease. , 2005, , 612-622.		0
529	Reply: The variability of levodopa response in Parkinson's disease: Is sensitization reversible?. Movement Disorders, 2008, 23, 925-925.	3.9	0
530	Reply to Drs. Kurlan, Fasano, and Evans: A clinically useful definition of stereotypies. Movement Disorders, 2013, 28, 405-406.	3.9	0
531	Reply to letter: multiple system atrophy-parkinsonism with slow progression and prolonged survival: A diagnostic catch. Movement Disorders, 2013, 28, 408-408.	3.9	0
532	Lessons learned: neuroprotective trials in Parkinson's disease. , 0, , 265-279.		0
533	The Clinical Spectrum of Functional/Psychogenic Dystonia. , 0, , 217-223.		0
534	Dancing Dorsal Quadrilateralsâ€”Organic or Functional?â€”Reply. JAMA Neurology, 2019, 76, 985.	9.0	0
535	Reply to â€œStudying reproducibility of data-driven Parkinson's disease subtypesâ€” Parkinsonism and Related Disorders, 2019, 66, 245-246.	2.2	0
536	Heart rate variability biomarkers of leucine-rich repeat kinase 2-associated Parkinson's disease. , 2020, , .		0
537	Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia. Movement Disorders, 2021, 36, 265-266.	3.9	0
538	Hyperglycemic hemichorea presenting with normal MRI and striatal hyperdensity on CT. Neurological Sciences, 2021, 42, 4341-4343.	1.9	0
539	Sleepiness and Sleep Attacks in Parkinsonâ€™s Disease. Advances in Behavioral Biology, 2002, , 385-390.	0.2	0
540	Psychogenic Dystonia. Medical Psychiatry, 2006, , 277-288.	0.2	0

#	ARTICLE	IF	CITATIONS
541	Psychogenic dystonia. , 2012, , 307-319.		0
542	Isolated Ear Clicks with Partial Voluntary Control. Tremor and Other Hyperkinetic Movements, 2020, 10, 55.	2.0	0